



June 29, 2022

Dear Provider,

We appreciate all that you are doing to take care of Texans with COVID-19. With COVID-19 cases and hospitalizations again rising in Texas, we want to remind you of the COVID-19 therapeutics available for high-risk patients with mild to moderate COVID-19.

Per the [NIH Guidelines for Therapeutic Management of Non-hospitalized Adults](#) update on April 8, 2022, the preferred therapies are listed in order of preference:

- Paxlovid
- Veklury (remdesivir)

Alternative therapies for use when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:

- Bebtelovimab
- Lagevrio (molnupiravir)

Please use your best clinical judgement in working through the NIH guidelines and consider prescribing the oral antiviral medication, Paxlovid, to all patients who are eligible. Paxlovid is widely available for high-risk Texans with symptomatic COVID-19; bebtelovimab remains the therapeutic with the most limited supply. Considering Paxlovid first will help preserve the other options for patients who need them. Patients and clinicians can use the [US HHS Therapeutics Locator](#) to find the nearest pharmacy with Paxlovid in stock.

Providers and patients can access additional information and resources through the following links.

- DSHS COVID-19 Therapeutics and Treatments Page (PROVIDERS)
<https://www.dshs.texas.gov/coronavirus/therapeutics-providers.aspx>
- DSHS COVID-19 Therapeutics and Treatments Page (PATIENTS)
<https://www.dshs.texas.gov/coronavirus/therapeutics/>